Table 1.
SARS-CoV-2 therapeutic approaches
| Therapeutic approach | Number of studies | CT number | Status | Phase | The product used |
|---|---|---|---|---|---|
| MSC | 65 |
Recruiting Recruiting Recruiting Not yet recruiting Enrolling by invitation Completed Recruiting Enrolling by invitation Recruiting Recruiting Completed Recruiting Recruiting Completed Recruiting Not yet recruiting Recruiting Recruiting Recruiting Recruiting Enrolling by invitation Not yet recruiting Recruiting Recruiting Not yet recruiting Recruiting Recruiting Active, not recruiting Not yet recruiting Not yet recruiting Recruiting Not yet recruiting Active, not recruiting Active, not recruiting Not yet recruiting Not yet recruiting Recruiting Recruiting Not yet recruiting Not yet recruiting Recruiting Recruiting Active, not recruiting Recruiting Not yet recruiting Recruiting Recruiting Not yet recruiting Recruiting Not yet recruiting Recruiting Not yet recruiting Recruiting Not yet recruiting Recruiting Not yet recruiting Not yet recruiting Not yet recruiting Not yet recruiting Recruiting Recruiting Available |
II/III I/II I/II I II II II II I I/II I I II II I - I/II I/II I II I I/II I I II II II I/II I I/II I I I/II I II I II II I/II I II I/II I/II I/II I/II II I/II II I III II I I II I II I II I/II I/II |
MSC, MSC + MSC-EVs UC-MSC Placenta-derived MSC/UC-MSC Allogenic AD-MSC AD-MSC Peripheral blood stem cells BM-MSC Autologous AD-MSC MSC MSC UC-MSC Allogenic BM-MSC UC-MSC UC-MSC MSC UC-MSC CAStem; regulatory cells from (hESCs) CYP-001(MSC from iPS) Wj-MSC BM-MSC Olfactory mucosa-derived MSCs Cord-blood MSC Cord-blood MSC MSC AD-MSC UC-MSC UC-MSC WJ-MSC WJ-MSC MSC UC-MSC BM-MSC UC-MSC AD-MSC MSC AD-MSC MSC DP-MSC UC-MSC AD-MSC WJ-MSC AD-MSC hCT-MSC UC-MSC UC-LSC UC-MSC UC-MSC Remestemcel-L BM-MSC BM-MSC Autologous AD-MSC placental mesenchymal-like adherent stromal cells DP-MSC MSC MSC NestaCell® UC-MSC MSCs or MSCs RNA-engineered UC-MSC MultiStem; BM-MSC |
|
| T cell | 7 |
Recruiting Recruiting Not yet recruiting Active, not recruiting Not yet recruiting Not yet recruiting Recruiting |
I I/II I/II I II I I |
Convalescent donor Convalescent donors RAPA-501-ALLO (allogeneic hybrid TREG/Th2 Cells) T cell-derived exosomes Viral-specific T cells Specific T cell cord blood-derived T regulatory cells |
|
| NK cell | 5 |
Recruiting Recruiting Recruiting Not yet recruiting Recruiting |
I/II I/II I I/II I |
NKG2D-ACE2 CAR-NK CYNK-001(human placental) NK Allogeneic NK cell transfer NK cell derived from an iPSC |
|
| CD34+ cells | 1 | NCT04522817 | Not yet recruiting | I | Peripheral blood-derived autologous CD34+ cells |
| Acellular product | 1 | NCT04384445 | Recruiting | I/II | Zofin; human amniotic fluid (HAF) |
| Monoclonal antibody | 80 |
Not yet recruiting Not yet recruiting Recruiting Recruiting Recruiting Not yet recruiting Recruiting Available Recruiting Recruiting Recruiting Recruiting Recruiting Recruiting Not yet recruiting Recruiting Recruiting Recruiting Recruiting Recruiting Recruiting Active, not recruiting Recruiting Not yet recruiting Recruiting Active, not recruiting Not yet recruiting Recruiting Recruiting Not yet recruiting Recruiting Recruiting Recruiting Not yet recruiting Recruiting Not yet recruiting Recruiting Recruiting Recruiting Active, not recruiting Active, not recruiting Recruiting Active, not recruiting Available Recruiting Recruiting Recruiting Recruiting Not yet recruiting Recruiting Recruiting Recruiting Recruiting Not yet recruiting Recruiting Active, not recruiting Active, not recruiting Completed Not yet recruiting Completed Recruiting Not yet recruiting Recruiting Not yet recruiting Recruiting Recruiting Recruiting Recruiting Recruiting Active, not recruiting Recruiting Completed Not yet recruiting Completed Completed Recruiting Recruiting |
II II I I/II IV - II - I - I/II I/II I II II III I/II I II II/III III I II/III I II II I II - III II IV I II II/III II I II II II/III II II II - III II II II III III II II II II II III III III II II II III III III - II I - - II II - III - II/III III - |
Nivolumab PD-1 blocking antibody monoclonal antibody targeting the CD73 Ruxolitinib is an inhibitor of JAK1/2 Ravulizumab/Baricitinib Ruxolitinib Ibrutinib IC14, against human CD14 Anti-SARS-CoV-2 Anti-SARS-CoV-2 Anti-Spike (S) Anti-Spike (S) Anti-SARS-CoV-2 Garadacimab; anti-factor XIIa Antibody to CD14 Lenzilumab; anti GM-CSF Anti GM-CSF Anti-Spike (S) Pamrevlumab; anti-Connective tissue growth factor Anti-SARS-CoV-2 Anti-Spike (S) Anti-SARS-CoV-2 Emapalumab/anakinra Anti-Spike (S) Gimsilumab; Anti GM-CSF Leronlimab; Anti-CCR5 Sarilumab; Anti-IL-6 Sarilumab; Anti-IL-6 Bevacizumab; Anti-VEGF Ravulizumab; Anti- Complement component 5 Crizanlizumab; anti-P-selectin Tocilizumab; anti-IL-6R AK119; anti-CD73 CSL324; anti-GCSF Mavrilimumab; anti-GM-CSF-Rα Mavrilimumab; anti-GM-CSF-Rα Anti-Spike (S) Tocilizumab; anti-IL-6R Leronlimab; anti-complement component 5 Sarilumab; anti-IL-6 Canakinumab; anti-IL-1-β Tocilizumab; anti-IL-6R Tocilizumab; anti-IL-6R Eculizumab; anti-complement component 5 Ravulizumab; anti-complement component 5 Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab/anakinra Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Anakinra, Tocilizumab, Ruxolitinib Tocilizumab Tocilizumab, Pembrolizumab Tocilizumab Tocilizumab Tocilizumab Tocilizumab Anakinra, Tocilizumab Tocilizumab Tocilizumab Tocilizumab Olokizumab Anakinra, Tocilizumab, Siltuximab Tocilizumab |
|
| Nanoparticle | 6 |
Not yet recruiting Recruiting Recruiting Completed Enrolling by invitation Not yet recruiting |
I I II I I/II II |
DeltaRex-G; mimic RNA virus SARS-CoV-2 by binding to viral receptors in human cells and may serve as a decoy Polymerized-type I collagen Inhaled IFN-β MSCs-derived exosomes MSCs-derived exosomes BM-derived MSC |
|
| Polyclonal antibody | 1 | NCT04453384 | Recruiting | II | Swine glyco-humanized polyclonal antibody |